MergerJul 20, 2026, 07:33 AM
Standard BioTools Files S-4 for Treeline Merger; TLN-121 Shows 84% ORR
AI Summary
Standard BioTools Inc. announced the filing of a registration statement on Form S-4 with the SEC in connection with its definitive merger agreement with Treeline Biosciences, Inc. The combined company is expected to have over $900 million in cash at closing, funding operations into 2029. Treeline also reported positive headline Phase 1 monotherapy data for TLN-121, showing an 84% overall response rate and 32% complete response rate in relapsed or refractory lymphomas, with no dose-limiting toxicities. Sue Desmond-Hellmann has joined Treeline's Board of Directors.
Key Highlights
- Standard BioTools filed Form S-4 for its merger with Treeline Biosciences.
- Combined company expected to have over $900 million cash at closing.
- TLN-121 Phase 1 monotherapy showed 84% overall response rate (ORR).
- TLN-121 Phase 1 monotherapy showed 32% complete response rate (CR).
- No dose-limiting toxicities reported for TLN-121.
- Interim data readouts for TLN-121 and TLN-372 planned for 2027.
- Sue Desmond-Hellmann joined Treeline's Board of Directors.
- Merger expected to close in the second half of 2026.
Price Impact
More from LAB